{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T01:11:33Z","timestamp":1785633093226,"version":"3.56.0"},"reference-count":143,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Precise estimation of a patient\u2019s drug metabolism capacity is important for antiseizure dose personalization.<\/jats:p><\/jats:sec>Objective<\/jats:title>To quantify the differences in plasma concentrations for antiseizure drugs associated with variants of genes encoding drug metabolizing enzymes.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>PubMed, Clinicaltrialsregister.eu, ClinicalTrials.gov, International Clinical Trials Registry Platform, and CENTRAL databases were screened for studies from January 1, 1990, to September 30, 2023, without language restrictions.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Two reviewers performed independent study screening and assessed the following inclusion criteria: appropriate genotyping was performed, genotype-based categorization into subgroups was possible, and each subgroup contained at least 3 participants.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed for data extraction and subsequent quality, validity, and risk-of-bias assessments. The results from the included studies were pooled with random-effect meta-analysis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Plasma concentrations of antiseizure drugs were quantified with the dose-normalized area under the concentration-time curve, the dose-normalized steady state concentration, or the concentrations after a single dose at standardized dose and sampling time. The ratio of the means was calculated by dividing the mean drug plasma concentrations of carriers and noncarriers of the pharmacogenetic variant.<\/jats:p><\/jats:sec>Results<\/jats:title>Data from 98 studies involving 12\u202f543 adult participants treated with phenytoin, valproate, lamotrigine, or carbamazepine were analyzed. Studies were mainly conducted within East Asian (69 studies) or White or European (15 studies) cohorts. Significant increases of plasma concentrations compared with the reference subgroup were observed for phenytoin, by 46% (95% CI, 33%-61%) in CYP2C9<\/jats:italic> intermediate metabolizers, 20% (95% CI, 17%-30%) in CYP2C19<\/jats:italic> intermediate metabolizers, and 39% (95% CI, 24%-56%) in CYP2C19<\/jats:italic> poor metabolizers; for valproate, by 12% (95% CI, 4%-20%) in CYP2C9<\/jats:italic> intermediate metabolizers, 12% (95% CI, 2%-24%) in CYP2C19<\/jats:italic> intermediate metabolizers, and 20% (95% CI, 2%-41%) in CYP2C19<\/jats:italic> poor metabolizers; and for carbamazepine, by 12% (95% CI, 3%-22%) in CYP3A5<\/jats:italic> poor metabolizers.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This systematic review and meta-analysis found that CYP2C9<\/jats:italic> and CYP2C19<\/jats:italic> genotypes encoding low enzymatic capacity were associated with a clinically relevant increase in phenytoin plasma concentrations, several pharmacogenetic variants were associated with statistically significant but only marginally clinically relevant changes in valproate and carbamazepine plasma concentrations, and numerous pharmacogenetic variants were not associated with statistically significant differences in plasma concentrations of antiseizure drugs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.25593","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:06:04Z","timestamp":1723129564000},"page":"e2425593","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs"],"prefix":"10.1001","volume":"7","author":[{"given":"Filip","family":"Milosavljevi\u0107","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"},{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Manojlovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Matkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"},{"name":"Institute for Mental Health, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway"},{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin M.","family":"Juki\u0107","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"},{"name":"Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"zoi240798r1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neulet.2017.01.014","article-title":"Pharmacogenomics in epilepsy.","volume":"667","author":"Balestrini","year":"2018","journal-title":"Neurosci Lett"},{"issue":"10","key":"zoi240798r2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/pgs-2020-0151","article-title":"A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters.","volume":"22","author":"Kanjanasilp","year":"2021","journal-title":"Pharmacogenomics"},{"issue":"10","key":"zoi240798r3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.21037\/atm","article-title":"The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis.","volume":"9","author":"Fang","year":"2021","journal-title":"Ann Transl Med"},{"issue":"7","key":"zoi240798r4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5414\/CP203083","article-title":"The association between CYP2C9\/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: a systematic review and meta-analysis.","volume":"56","author":"Liao","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"zoi240798r5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00228-020-02872-6","article-title":"Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.","volume":"76","author":"Yoon","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"zoi240798r6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5414\/CP203357","article-title":"A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics.","volume":"57","author":"Kim","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"zoi240798r7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00228-017-2395-z","article-title":"Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.","volume":"74","author":"Wang","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"41","key":"zoi240798r8","first-page":"3365","article-title":"Relationship between UGT1A4 142T>G polymorphism and serum concentration of lamotrigine in Chinese epileptic patients: a meta-analysis.","volume":"98","author":"Li","year":"2018","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"zoi240798r9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.2019.124.issue-2","article-title":"Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration.","volume":"124","author":"Kim","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"zoi240798r10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jocn.2021.07.009","article-title":"Association of EPHX1 polymorphisms with plasma concentration of carbamazepine in epileptic patients: systematic review and meta-analysis.","volume":"91","author":"Hu","year":"2021","journal-title":"J Clin Neurosci"},{"key":"zoi240798r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145907","article-title":"ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.","volume":"805","author":"Zhang","year":"2021","journal-title":"Gene"},{"key":"zoi240798r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106615","article-title":"Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis.","volume":"173","author":"Zhao","year":"2021","journal-title":"Epilepsy Res"},{"issue":"3","key":"zoi240798r13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis.","volume":"78","author":"Milosavljevic","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"44","key":"zoi240798r14","doi-asserted-by":"publisher","first-page":"E1499","DOI":"10.1503\/cmaj.221785","article-title":"Cost-effectiveness of pharmacogenomic-guided treatment for major depression.","volume":"195","author":"Ghanbarian","year":"2023","journal-title":"CMAJ"},{"issue":"1-02","key":"zoi240798r16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"zoi240798r17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/FPC.0b013e328348c6f2","article-title":"PharmGKB summary: carbamazepine pathway.","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"zoi240798r18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/FPC.0000000000000397","article-title":"PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics.","volume":"30","author":"Mitra-Ghosh","year":"2020","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"zoi240798r19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/FPC.0b013e32834aeedb","article-title":"PharmGKB summary: phenytoin pathway.","volume":"22","author":"Thorn","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"zoi240798r20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics.","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"zoi240798r21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.","volume":"17","author":"Zhou","year":"2023","journal-title":"Hum Genomics"},{"issue":"5","key":"zoi240798r22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"zoi240798r23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2133\/dmpk.DMPK-10-SC-021","article-title":"Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population.","volume":"25","author":"Hwang","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"zoi240798r24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clinbiochem.2006.01.002","article-title":"Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects.","volume":"39","author":"Saito","year":"2006","journal-title":"Clin Biochem"},{"issue":"3","key":"zoi240798r25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II: functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"zoi240798r26","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"zoi240798r27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13643-023-02217-1","article-title":"Ten circumstances and solutions for finding the sample mean and standard deviation for meta-analysis.","volume":"12","author":"Chi","year":"2023","journal-title":"Syst Rev"},{"key":"zoi240798r28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study.","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"zoi240798r29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"zoi240798r30","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"zoi240798r32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40262-022-01141-2","article-title":"Phenytoin metabolic ratio, a marker of CYP2C9 activity, is superior to the CYP2C9 genotype as a predictor of (S)-warfarin clearance.","volume":"61","author":"Shaul","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"zoi240798r33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/cpt.v112.1","article-title":"The impact of CYP2C9*11 allelic variant on the pharmacokinetics of phenytoin and (S)-warfarin.","volume":"112","author":"Wanounou","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"zoi240798r34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/FPC.0000000000000383","article-title":"Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.","volume":"29","author":"Fohner","year":"2019","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"zoi240798r35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/ph10030073","article-title":"Role of CYP2C9, CYP2C19 and EPHX polymorphism in the pharmacokinetic of phenytoin: a study on Uruguayan Caucasian subjects.","volume":"10","author":"Guevara","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"zoi240798r36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2174\/1389200217666160513132716","article-title":"Population pharmacokinetics of phenytoin based on NONMEM in patients with intracranial tumor during the first week of post-craniotomy.","volume":"17","author":"Li","year":"2016","journal-title":"Curr Drug Metab"},{"issue":"3","key":"zoi240798r37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/tpj.2015.45","article-title":"CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.","volume":"16","author":"Ortega-V\u00e1zquez","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"zoi240798r38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4103\/0028-3886.156281","article-title":"Critical appraisal of serum phenytoin variation with patient characteristics in a North Indian population.","volume":"63","author":"Sharma","year":"2015","journal-title":"Neurol India"},{"issue":"2","key":"zoi240798r39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/FTD.0000000000000128","article-title":"Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.","volume":"37","author":"Yamamoto","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"4","key":"zoi240798r40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4103\/0253-7613.99314","article-title":"Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug.","volume":"44","author":"George","year":"2012","journal-title":"Indian J Pharmacol"},{"issue":"12","key":"zoi240798r41","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/pgs.12.117","article-title":"Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"7","key":"zoi240798r42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00228-010-0817-2","article-title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.","volume":"66","author":"Kesavan","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"zoi240798r43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1592\/phco.28.1.35","article-title":"Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.","volume":"28","author":"Lin","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"3","key":"zoi240798r44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.5483\/BMBRep.2007.40.3.448","article-title":"Contributions of CYP2C9\/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.","volume":"40","author":"Lee","year":"2007","journal-title":"J Biochem Mol Biol"},{"issue":"5","key":"zoi240798r45","first-page":"665","article-title":"Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.","volume":"123","author":"Rosemary","year":"2006","journal-title":"Indian J Med Res"},{"issue":"2","key":"zoi240798r46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2133\/dmpk.20.135","article-title":"Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases.","volume":"20","author":"Yamanaka","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"zoi240798r47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2133\/dmpk.20.107","article-title":"Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.","volume":"20","author":"Taguchi","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"zoi240798r48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/00007691-200410000-00012","article-title":"Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9\/CYP2C19 polymorphisms.","volume":"26","author":"Hung","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"7","key":"zoi240798r49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.lfs.2003.07.018","article-title":"CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.","volume":"74","author":"Soga","year":"2004","journal-title":"Life Sci"},{"issue":"7","key":"zoi240798r50","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/00008571-200110000-00005","article-title":"Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.","volume":"11","author":"Caraco","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"4","key":"zoi240798r51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00008571-200106000-00002","article-title":"The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.","volume":"11","author":"van der Weide","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"3","key":"zoi240798r52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2125.1999.00012.x","article-title":"Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.","volume":"48","author":"Aynacioglu","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"zoi240798r53","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/epi.1998.39.issue-12","article-title":"The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.","volume":"39","author":"Mamiya","year":"1998","journal-title":"Epilepsia"},{"issue":"20","key":"zoi240798r54","first-page":"1686","article-title":"Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration.","volume":"84","author":"Huang","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"3","key":"zoi240798r55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10072-018-3681-y","article-title":"Lack of association between valproic acid response and polymorphisms of its metabolism, transport, and receptor genes in children with focal seizures.","volume":"40","author":"Feng","year":"2019","journal-title":"Neurol Sci"},{"issue":"10","key":"zoi240798r56","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.13040\/IJPSR.0975-8232","article-title":"The effect of UGT1A6 polymorphism at two loci on the clinical response to valproic acid in epileptic children.","volume":"7","author":"Algharably","year":"2016","journal-title":"Int J Pharm Sci Res"},{"issue":"11","key":"zoi240798r57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2217\/pgs-2016-0030","article-title":"Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.","volume":"17","author":"Wen","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"4","key":"zoi240798r58","first-page":"4513","article-title":"Effects of UGT1A3, UGT1A6, and UGT2B7 genetic polymorphisms on plasma concentration of valproic acid in south Chinese epilepsy patients.","volume":"9","author":"Shen","year":"2016","journal-title":"Int J Clin Exp Pathol"},{"key":"zoi240798r59","first-page":"41","article-title":"Effect of UGT1A6*2 genetic polymorphism on the doses, plasma concentration and metabolism of valproic acid in patients with epilepsy from R. Macedonia.","volume":"53","author":"Sterjev","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"zoi240798r60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2217\/pgs-2022-0156","article-title":"Effects of UGT1A, CYP2C9\/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients.","volume":"24","author":"Zheng","year":"2023","journal-title":"Pharmacogenomics"},{"issue":"1","key":"zoi240798r61","doi-asserted-by":"publisher","first-page":"23150","DOI":"10.1038\/s41598-021-02628-x","article-title":"Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"zoi240798r62","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/00498254.2021.1931554","article-title":"Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children.","volume":"51","author":"Du","year":"2021","journal-title":"Xenobiotica"},{"key":"zoi240798r63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/PGPM.S301893","article-title":"CYP2C9*3\/*3 gene expression affects the total and free concentrations of valproic acid in pediatric patients with epilepsy.","volume":"14","author":"Wu","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"zoi240798r64","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.599044","article-title":"Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy.","volume":"8","author":"Xu","year":"2021","journal-title":"Front Pediatr"},{"issue":"8","key":"zoi240798r65","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12098-020-03565-9","article-title":"UGT1A6 and UGT2B7 gene polymorphism and its effect in pediatric epileptic patients on sodium valproate monotherapy.","volume":"88","author":"Nandith","year":"2021","journal-title":"Indian J Pediatr"},{"issue":"4","key":"zoi240798r66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/ejhpharm-2020-002367","article-title":"Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.","volume":"29","author":"Song","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"zoi240798r67","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/FTD.0000000000000751","article-title":"Impact of age and genotype on serum concentrations of valproic acid and its hepatotoxic metabolites in Chinese pediatric patients with epilepsy.","volume":"42","author":"Zhao","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"3","key":"zoi240798r68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.therap.2019.07.003","article-title":"Association of UGT2B7 and CAMK4 with response of valproic acid in Chinese children with epilepsy.","volume":"75","author":"Wang","year":"2020","journal-title":"Therapie"},{"issue":"3","key":"zoi240798r69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/pme.14.82","article-title":"Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy.","volume":"12","author":"T\u00f3th","year":"2015","journal-title":"Per Med"},{"key":"zoi240798r70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.seizure.2018.04.006","article-title":"Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures.","volume":"58","author":"Feng","year":"2018","journal-title":"Seizure"},{"issue":"2","key":"zoi240798r71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.braindev.2017.09.004","article-title":"Correlations between UGT2B7*2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients.","volume":"40","author":"Zhang","year":"2018","journal-title":"Brain Dev"},{"issue":"1","key":"zoi240798r72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13049-017-0382-0","article-title":"Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6\/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.","volume":"25","author":"Sun","year":"2017","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"zoi240798r73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.seizure.2017.07.005","article-title":"Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.","volume":"51","author":"Mei","year":"2017","journal-title":"Seizure"},{"issue":"4","key":"zoi240798r74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/FTD.0000000000000424","article-title":"Analysis of the variables influencing valproic acid concentration in the serum and cerebrospinal fluid of Chinese patients after craniotomy.","volume":"39","author":"Li","year":"2017","journal-title":"Ther Drug Monit"},{"key":"zoi240798r75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.eplepsyres.2017.02.015","article-title":"Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.","volume":"132","author":"Wang","year":"2017","journal-title":"Epilepsy Res"},{"issue":"2","key":"zoi240798r76","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bcpt.2017.121.issue-2","article-title":"Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity.","volume":"121","author":"Zhao","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"zoi240798r77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","article-title":"Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.","volume":"130","author":"Jogamoto","year":"2017","journal-title":"Epilepsy Res"},{"issue":"6","key":"zoi240798r78","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","article-title":"Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China.","volume":"38","author":"Feng","year":"2016","journal-title":"Ther Drug Monit"},{"key":"zoi240798r79","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.12659\/MSM.897626","article-title":"Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in Children.","volume":"22","author":"Du","year":"2016","journal-title":"Med Sci Monit"},{"issue":"9","key":"zoi240798r80","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.","volume":"72","author":"Smith","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"zoi240798r81","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/pgs-2016-0014","article-title":"UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.","volume":"17","author":"Chatzistefanidis","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"3","key":"zoi240798r82","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine.","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"zoi240798r83","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients.","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res"},{"issue":"1","key":"zoi240798r84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/0028-3886.152631","article-title":"Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy.","volume":"63","author":"Jain","year":"2015","journal-title":"Neurol India"},{"issue":"3","key":"zoi240798r85","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"8","key":"zoi240798r86","first-page":"766","article-title":"Effect of UGT2B7 genetic variants on serum valproic acid concentration.","volume":"38","author":"Ma","year":"2013","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"10","key":"zoi240798r87","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"zoi240798r88","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization.","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"4","key":"zoi240798r89","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"zoi240798r90","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","article-title":"Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.","volume":"83","author":"Chung","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"zoi240798r91","first-page":"429","article-title":"Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan.","volume":"12","author":"Wang","year":"2010","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"29","key":"zoi240798r92","first-page":"2033","article-title":"Effect of UGTIA6 genetic polymorphisms on the metabolism of sodium valproate [article in Chinese].","volume":"87","author":"Sun","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"zoi240798r93","doi-asserted-by":"publisher","first-page":"S387","DOI":"10.1016\/S0924-977X(13)70611-4","article-title":"2. d. 040 Psychiatric patients carrying the CYP2C9*2 allele require lower doses of valproic acid to achieve target plasma levels.","volume":"23","author":"Rutigliano","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"zoi240798r94","first-page":"82","article-title":"Effects of cytochrome P450 isozymes 2A6,286,2C9 and 2C19 genetic polymorphisms on plasma concentration of sodium valproate.","volume":"46","author":"Liao","year":"2013","journal-title":"Chin J Neurol"},{"issue":"4","key":"zoi240798r95","first-page":"280","article-title":"Relationship between UGT1A6 A541G and A552C genetic polymorphism and plasma concentration of sodium valproate.","volume":"18","author":"Kang","year":"2016","journal-title":"Chin J Health Care Med."},{"issue":"6","key":"zoi240798r96","first-page":"802","article-title":"Effect of UGT1A6 genetic polymorphism on serum concentration of valproic acid in Han epileptic patients.","volume":"16","author":"Jin","year":"2013","journal-title":"China Pharm"},{"issue":"3","key":"zoi240798r97","first-page":"295","article-title":"Effects of CYP2C19 genetic polymorphism on plasma concentration of sodium valproate in epileptic patients.","volume":"4","author":"Han","year":"2015","journal-title":"Neural Injury Funct Reconstr."},{"issue":"2","key":"zoi240798r98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.56808\/3027-7922.1977","article-title":"Association of genetic variants in UGT1A6 genes and non-genetic variant with valproic acid doses and plasma concentration in Thai epileptic patients.","volume":"38","author":"Aphichartphunkawee","year":"2014","journal-title":"Thaiphesatchasan"},{"issue":"8","key":"zoi240798r99","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00228-023-03526-z","article-title":"Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7-161C?>?T (rs7668258) or UGT1A4*3 c.142 T?>?G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.","volume":"79","author":"Bo\u017eina","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi240798r100","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106897","article-title":"Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients.","volume":"182","author":"Petrenaite","year":"2022","journal-title":"Epilepsy Res"},{"issue":"6","key":"zoi240798r101","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41397-020-0173-2","article-title":"Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.","volume":"20","author":"Ortega-V\u00e1zquez","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"zoi240798r102","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000577","article-title":"Relationship between UGT1A4 and UGT2B7 polymorphisms and the steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy.","volume":"41","author":"Suzuki","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"5","key":"zoi240798r103","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/FTD.0000000000000540","article-title":"Clinically relevant effect of UGT1A4*3 on lamotrigine serum concentration is restricted to postmenopausal women\u2014a study matching therapeutic drug monitoring and genotype data from 534 patients.","volume":"40","author":"Smith","year":"2018","journal-title":"Ther Drug Monit"},{"key":"zoi240798r104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","article-title":"UGT polymorphisms and lamotrigine clearance during pregnancy.","volume":"140","author":"Petrenaite","year":"2018","journal-title":"Epilepsy Res"},{"issue":"11","key":"zoi240798r105","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C?>?T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.","volume":"71","author":"Liu","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"zoi240798r106","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.dmpk.2015.05.002","article-title":"Polymorphisms of ABCG2, ABCB1 and HNF4a are associated with lamotrigine trough concentrations in epilepsy patients.","volume":"30","author":"Zhou","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"zoi240798r107","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.dmpk.2014.12.007","article-title":"Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.","volume":"30","author":"Wang","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"zoi240798r108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","article-title":"Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.","volume":"41","author":"Reimers","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"20","key":"zoi240798r109","first-page":"2737","article-title":"Quantitative estimation of blood concentration of lamotrigine in Chinese Han pediatric patients with epilepsy based on UGT1A4 142T>G polymorphism and blood concentration of valproic acid.","volume":"28","author":"He","year":"2017","journal-title":"Chin Pharm"},{"issue":"8","key":"zoi240798r110","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China.","volume":"70","author":"Chang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"zoi240798r111","first-page":"39","article-title":"Association study of genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients.","volume":"16","author":"Meng","year":"2011","journal-title":"Neurol Asia"},{"issue":"3","key":"zoi240798r112","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/ijp.ijp_228_22","article-title":"Genetic polymorphisms of microsomal epoxide hydrolase and UDP-glucuronosyltransferase (UGT) and its effects on plasma carbamazepine levels and metabolic ratio in persons with epilepsy of South India: a cross-sectional genetic association study.","volume":"55","author":"Venkatraman","year":"2023","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"zoi240798r113","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4103\/ijp.IJP_122_19","article-title":"Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.","volume":"51","author":"Ganesapandian","year":"2019","journal-title":"Indian J Pharmacol"},{"issue":"30","key":"zoi240798r114","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011662","article-title":"Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"zoi240798r115","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/01677063.2016.1155571","article-title":"Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.","volume":"30","author":"Chbili","year":"2016","journal-title":"J Neurogenet"},{"issue":"11","key":"zoi240798r116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142408","article-title":"Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients.","volume":"10","author":"Daci","year":"2015","journal-title":"PLoS One"},{"key":"zoi240798r117","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"issue":"13","key":"zoi240798r118","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2217\/pgs.15.94","article-title":"Association between PK\/PD-involved gene polymorphisms and carbamazepine-individualized therapy.","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"15","key":"zoi240798r119","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2217\/pgs.14.142","article-title":"Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.","volume":"15","author":"Zhu","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"zoi240798r120","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/FPC.0000000000000030","article-title":"Pregnane X receptor and hepatocyte nuclear factor 4a polymorphisms are cooperatively associated with carbamazepine autoinduction.","volume":"24","author":"Saruwatari","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"zoi240798r121","doi-asserted-by":"publisher","first-page":"502","DOI":"10.18433\/J3Q888","article-title":"Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients.","volume":"16","author":"Panomvana","year":"2013","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"zoi240798r122","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eplepsyres.2013.09.011","article-title":"Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.","volume":"107","author":"Yun","year":"2013","journal-title":"Epilepsy Res"},{"issue":"2","key":"zoi240798r123","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/pgs.11.141","article-title":"Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"5","key":"zoi240798r124","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/jcp.2009.34.issue-5","article-title":"Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.","volume":"34","author":"Park","year":"2009","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"zoi240798r125","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clpt.2006.02.009","article-title":"Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy.","volume":"79","author":"Seo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"zoi240798r126","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.5958\/0974-360X.2020.00498.9","article-title":"Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients.","volume":"13","author":"Pham","year":"2020","journal-title":"Res J Pharm Tech."},{"issue":"19","key":"zoi240798r127","first-page":"1749","article-title":"Effect of cytochrome P450 3A4 and 3A5 genotype on carbamazepine serum concentrations at steady-state and carbamazepine-induced cutaneous adverse drug reactions.","author":"Liu","year":"2016","journal-title":"Chin J Clin Pharmacol"},{"issue":"36","key":"zoi240798r128","first-page":"3433","article-title":"Effects of CYP3A5 gene polymorphism on steady state serum concentrations and therapeutic efficacy of carbamazepine in Chinese Han epileptic patients.","author":"Liu","year":"2014","journal-title":"China Pharm"},{"issue":"6","key":"zoi240798r129","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/FTD.0b013e3181fa97cc","article-title":"Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.","volume":"32","author":"Ramasamy","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"3","key":"zoi240798r130","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects.","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"zoi240798r131","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1212\/WNL.0000000000200779","article-title":"Changes in the use of brand name and generic medications and total prescription cost among medicare beneficiaries with epilepsy.","volume":"99","author":"Terman","year":"2022","journal-title":"Neurology"},{"key":"zoi240798r132","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108841","article-title":"Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: a retrospective cohort study using the database of health insurance claims between 2015 and 2019.","volume":"134","author":"Jin","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"8","key":"zoi240798r135","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1517\/17425255.2015.1053463","article-title":"CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.","volume":"11","author":"Franco","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"zoi240798r137","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"zoi240798r141","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/epi.2017.58.issue-7","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non\u2013protein-bound concentrations.","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia"},{"issue":"9","key":"zoi240798r142","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/00008571-200112000-00008","article-title":"Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.","volume":"11","author":"Kidd","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"1","key":"zoi240798r143","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00008571-199902000-00010","article-title":"Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.","volume":"9","author":"Kidd","year":"1999","journal-title":"Pharmacogenetics"},{"key":"zoi240798r136","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"zoi240798r15","unstructured":"Clinical Pharmacogenetics Implementation Consortium. Accessed on January 16, 2024. https:\/\/cpicpgx.org\/"},{"key":"zoi240798r31","unstructured":"US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014general considerations. Accessed November 11, 2023. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf"},{"key":"zoi240798r133","unstructured":"US Food and Drug Administration. Table of Pharmacogenetic Associations. Accessed January 16, 2024. https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations"},{"key":"zoi240798r134","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Dilantin. Accessed January 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/084349s087lbl.pdf"},{"key":"zoi240798r138","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Depakene. Accessed January 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018081s065_018082s048lbl.pdf"},{"key":"zoi240798r139","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Lamictal. Accessed January 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020241s045s051lbl.pdf"},{"key":"zoi240798r140","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Tegretol. Accessed January 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/016608s097,018281s045,018927s038,020234s026lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822076\/milosavljevi_2024_oi_240798_1722527195.61385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:06:20Z","timestamp":1723129580000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822076"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":143,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.25593","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}